ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL190461
CHEMBL190461
Compound Name CANNABIDIOL
ChEMBL Synonyms CBD | GWP42003-P | CANNABIDIOL
Max Phase 3
Trade Names
Molecular Formula C21H30O2

Additional synonyms for CHEMBL190461 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCCCCc1cc(O)c([C@@H]2C=C(C)CC[C@H]2C(=C)C)c(O)c1
Standard InChI InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-1 ...
Download InChI
Standard InChI Key QHMBSVQNZZTUGM-ZWKOTPCHSA-N

Sources

  • Clinical Candidates
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names

Alternate Forms of Compound in ChEMBL


CHEMBL190461

Molecule Features

CHEMBL190461 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Unclassified Parenteral:Unclassified Topical:Unclassified Black Box:Unclassified Availability Type:Unclassified

Mechanism of Action

Mechanism of Action ChEMBL Target References
Cannabinoid CB1 receptor negative allosteric modulator Cannabinoid CB1 receptor PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Bipolar DisorderD001714EFO:0000289bipolar disorder2ClinicalTrials
Crohn DiseaseD003424EFO:0000384Crohn's disease1ClinicalTrials
Opioid-Related DisordersD009293EFO:0005611opioid dependence2ClinicalTrials
Amyotrophic Lateral SclerosisD000690EFO:0000253amyotrophic lateral sclerosis2ClinicalTrials
AnxietyD001007EFO:0005230anxiety2ClinicalTrials
Fatty LiverD005234HP:0001397Hepatic steatosis2ClinicalTrials
Parkinson DiseaseD010300EFO:0002508Parkinson's disease2ClinicalTrials
Stress Disorders, Post-TraumaticD013313EFO:0001358post-traumatic stress disorder2ClinicalTrials
EpilepsyD004827EFO:0000474epilepsy3ClinicalTrials
Lennox Gastaut SyndromeD065768Orphanet:2382Lennox-Gastaut syndrome3ClinicalTrials
Tobacco Use DisorderD014029EFO:0003768nicotine dependence2ClinicalTrials
Epilepsies, MyoclonicD004831Orphanet:33069Dravet syndrome3ClinicalTrials
Marijuana AbuseD002189EFO:0004218marijuana dependence2ClinicalTrials
PainD010146EFO:0003843pain3ClinicalTrials
SchizophreniaD012559EFO:0000692schizophrenia2ClinicalTrials
Cocaine-Related DisordersD019970EFO:0002610cocaine dependence2ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm2ClinicalTrials
Huntington DiseaseD006816Orphanet:399Huntington disease2ClinicalTrials
Psychotic DisordersD011618EFO:0005411schizoaffective disorder2ClinicalTrials
Sturge-Weber SyndromeD013341Orphanet:3205Sturge-Weber syndrome1ClinicalTrials
Colitis, UlcerativeD003093EFO:0000729ulcerative colitis2ClinicalTrials
Epilepsy, AbsenceD004832Orphanet:64280Childhood absence epilepsy2ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma1ClinicalTrials
Prader-Willi SyndromeD011218Orphanet:739Prader-Willi syndrome2ClinicalTrials
Spasms, InfantileD013036Orphanet:3451West syndrome3ClinicalTrials
Graft vs Host DiseaseD006086EFO:0004599acute graft vs. host disease2ClinicalTrials
SeizuresD012640HP:0001250Seizures3ClinicalTrials

Clinical Data

ClinicalTrials.gov CANNABIDIOL
The Cochrane Collaboration CANNABIDIOL

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL190461. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL5373 Cannabinoid CB2 receptor Mus musculus 1.000
CHEMBL3571 Cannabinoid CB1 receptor Rattus norvegicus 1.000
CHEMBL253 Cannabinoid CB2 receptor Homo sapiens 1.000
CHEMBL3037 Cannabinoid CB1 receptor Mus musculus 1.000
CHEMBL218 Cannabinoid CB1 receptor Homo sapiens 0.999
CHEMBL5160 Transient receptor potential cation channel subfamily A member 1 Rattus norvegicus 0.999
CHEMBL3998 Dopamine D2 receptor Bos taurus 0.969
CHEMBL3762 Voltage-gated L-type calcium channel alpha-1C subunit Rattus norvegicus 0.965
CHEMBL3911 Leukotriene B4 receptor 1 Homo sapiens 0.357
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.326
CHEMBL3318 Tyrosinase Agaricus bisporus 0.297



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL5373 Cannabinoid CB2 receptor Mus musculus 1.000
CHEMBL3571 Cannabinoid CB1 receptor Rattus norvegicus 1.000
CHEMBL253 Cannabinoid CB2 receptor Homo sapiens 1.000
CHEMBL5160 Transient receptor potential cation channel subfamily A member 1 Rattus norvegicus 1.000
CHEMBL218 Cannabinoid CB1 receptor Homo sapiens 0.999
CHEMBL3037 Cannabinoid CB1 receptor Mus musculus 0.992
CHEMBL3998 Dopamine D2 receptor Bos taurus 0.813
CHEMBL4394 Sphingosine kinase 1 Homo sapiens 0.773
CHEMBL3762 Voltage-gated L-type calcium channel alpha-1C subunit Rattus norvegicus 0.723
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.692
CHEMBL1828 DNA polymerase alpha subunit Homo sapiens 0.458
CHEMBL3911 Leukotriene B4 receptor 1 Homo sapiens 0.273
CHEMBL3775 Dual specificity phosphatase Cdc25A Homo sapiens 0.204

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
314.5 314.2246 5.85 6 40.46 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
2 2 1 2 2 1


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
9.64 - 6.6 6.6 1 23 0.51

Structural Alerts

There are 3 structural alerts for CHEMBL190461. To view alerts please click here.

Compound Cross References

ChemSpider ChemSpider:QHMBSVQNZZTUGM-ZWKOTPCHSA-N

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL190461



ACToR 13956-29-1
BindingDB 50121429 50318484
Brenda 62441
ChEBI 69478
ChemicalBook CB7673434
DrugBank DB09061
eMolecules 536311
FDA SRS 19GBJ60SN5
Guide to Pharmacology 4150
IBM Patent System CEBF98F49CD6C41BFCA4035F7E0B92C0
Metabolights MTBLC69478
Nikkaji J10.356J
PubChem 644019
PubChem: Drugs of the Future 12012585
PubChem: Thomson Pharma 14899058 14825860
SureChEMBL SCHEMBL119679
ZINC ZINC000004097406

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/QHMBSVQNZZTUGM-ZWKOTPCHSA-N spacer
spacer